Kineta PE Ratio 2014-2024 | KANT
Current and historical p/e ratio for Kineta (KANT) from 2014 to 2024. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Kineta PE ratio as of September 19, 2024 is 0.00.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Kineta PE Ratio Historical Data |
| Date |
Stock Price |
TTM Net EPS |
PE Ratio |
| 2024-09-18 |
0.57 |
|
0.00 |
| 2024-06-30 |
0.53 |
$-1.74 |
0.00 |
| 2024-03-31 |
0.53 |
$-1.50 |
0.00 |
| 2023-12-31 |
3.63 |
$-1.38 |
0.00 |
| 2023-09-30 |
3.40 |
$-1.19 |
0.00 |
| 2023-06-30 |
2.58 |
$-2.90 |
0.00 |
| 2023-03-31 |
3.31 |
$-6.09 |
0.00 |
| 2022-12-31 |
6.35 |
$-14.00 |
0.00 |
| 2022-09-30 |
1.57 |
$-20.99 |
0.00 |
| 2022-06-30 |
1.82 |
$-25.61 |
0.00 |
| 2022-03-31 |
1.50 |
$-29.67 |
0.00 |
| 2021-12-31 |
2.96 |
$-26.94 |
0.00 |
| 2021-09-30 |
10.32 |
$-19.94 |
0.00 |
| 2021-06-30 |
11.65 |
$-35.55 |
0.00 |
| 2021-03-31 |
18.10 |
$-52.13 |
0.00 |
| 2020-12-31 |
17.00 |
$-72.78 |
0.00 |
| 2020-09-30 |
22.00 |
$-104.97 |
0.00 |
| 2020-06-30 |
27.40 |
$-117.57 |
0.00 |
| 2020-03-31 |
22.80 |
$-148.36 |
0.00 |
| 2019-12-31 |
45.60 |
$-160.95 |
0.00 |
| 2019-09-30 |
16.90 |
$-179.15 |
0.00 |
| 2019-06-30 |
19.52 |
$-214.14 |
0.00 |
| 2019-03-31 |
25.20 |
$-219.73 |
0.00 |
| 2018-12-31 |
64.80 |
$-225.33 |
0.00 |
| 2018-09-30 |
48.20 |
$-246.33 |
0.00 |
| 2018-06-30 |
55.80 |
$-254.72 |
0.00 |
| 2018-03-31 |
95.00 |
$-289.71 |
0.00 |
| 2017-12-31 |
116.60 |
$-328.90 |
0.00 |
| 2017-09-30 |
42.00 |
$-310.71 |
0.00 |
| 2017-06-30 |
93.60 |
$-307.91 |
0.00 |
| 2017-03-31 |
156.40 |
$-278.52 |
0.00 |
| 2016-12-31 |
245.20 |
$-316.30 |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.000B |
$0.005B |
|
Kineta, Inc. is a clinical-stage biotechnology company. It develops next-generation immunotherapies that address the major challenges with current cancer therapy. The company's lead asset is KVA12123, a novel VISTA blocking immunotherapy. Kineta merged with Yumanity Therapeutics, Inc., and is based in Seattle.
|
